Go to the profile of Raveena Bhambra

Raveena Bhambra

Editor, BioPharma Dealmakers , Nature Research
  • Nature Research
  • Editors
  • United Kingdom
Founded in London (United Kingdom) in 2016, MicroQuin was born out of a collaborative and inclusive approach to research. MicroQuin is a biotechnology, R&D based company currently focusing on developing therapeutics to address a range of oncological disease. MicroQuin is progressing lead compounds into clinical trials, which offer a potential cure to Breast Cancer and other diseases.
Go to the profile of Albany A. Cordova Martins
Albany A. Cordova Martins

Business Development Executive, Nature Publishing Group, Springer Nature

Emotional Brain is based in Almere, the Netherlands, and conducts fundamental scientific research into the causes of female sexual dysfunction and clinical research into treatment options. Two new on-demand drugs with blockbuster potential, Lybrido and Lybridos, are in development. Moreover, Emotional Brain recently developed a novel method, based on genotyping using Single-Nucleotide Polymorphisms (SNPs) resulting in Phenotype Prediction Score (PPS) associated with traits and treatment effects. This innovative genetic method can be applied for the prediction whether someone is a responder or a non-responder to drug use (or traits). Other products are in early development stage. Over the years, Emotional Brain has published numerous well-cited papers in respected, peer-reviewed scientific journals such as Archives of General Psychiatry, the Journal of Sexual Medicine, Psychoneuroendocrinology and the British Journal of Clinical Pharmacology.
BrightPath Biotherapeutics, formerly GreenPeptide, is a Japan-based clinical-stage biopharmaceutical company focused on developing novel cancer immunotherapeutics. Our pipeline includes cancer peptide vaccine, rejuvenated T cell therapy, and immuno-modulator antibodies. Our basic business model covers research and early clinical development, followed by out-licensing to pharmaceutical companies, so we would like to take an opportunity to introduce our out-licensing candidates. We also search for in-licensing and/or research collaboration opportunities in I/O field.
Sinergium Biotech is an Argentine biopharmaceutical company specializing in the research, development, production and marketing of high complexity vaccines and biopharmaceuticals. With unique characteristics worldwide, it carries out an innovative productive model of strategic alliances with national and international laboratories that allows: the transfer and availability of state-of-the-art technologies, autonomy in production and provision of strategic products that were previously to be imported, Generation of new sources of work with highly qualified professionals, the replacement of imports and the generation of significant export potential.
A privately held clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, is pioneering messenger RNA (mRNA)-based medicines to transform how the human body prevents and fights disease.
Qurient is a ‘Network R&D company’ mainly focuses on development of novel therapeutics from late discovery to human proof of concept. Qurient has expertise in virtual R&D project management and operates through extensive network of research organizations.
Merus is a clinical-stage immuno-oncology company developing innovative full-length human bispecific antibody therapeutics, referred to as Biclonics®. Biclonics® are based on the full-length IgG format, are manufactured using industry standard processes and have been observed in preclinical studies to share several features of conventional monoclonal antibodies, such as long half-life and low immunogenicity. Merus' lead bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial in Europe as a potential treatment for HER2-expressing solid tumors. Merus' second bispecific antibody candidate, MCLA-117, is being developed in a Phase 1 clinical trial in patients with acute myeloid leukemia. The Company also has a pipeline of proprietary bispecific antibody candidates in preclinical development, including MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors, as well as Biclonics® designed to bind to various combinations of immunomodulatory molecules, including PD-1 and PD-L1.
Incorporated in 2000, Chimerix is a biopharmaceutical company discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus. We believe that antivirals that could reduce the frequency of these and other DNA viruses and potentially avoid increasing the risk of other opportunistic infections could provide measurable clinical and pharmacoeconomic benefits for patients and the healthcare system. Through work to date, we see significant opportunities to apply the lipid conjugate technology to other disease categories that are also characterized by a need for effective treatments.
ImmuneMed, Inc. is specialized to diagnose and treat the infectious diseases using antibody and antigen discovery technologies. ImmuneMed Inc. believes that the human immune system itself is the most effective defence system of our body in curing various infectious diseases. These beliefs have been a guiding principle for the company's research over the years. Using the innate immune system, a new antiviral therapeutic has been discovered and developed an endogenous broad-spectrum antiviral drug candidate called Virus suppressing factor (VSF). ImmuneMed has been further developing VSF to humanized VSF (hzVSF) as an immunoglobulin. ImmuneMed has demonstrated the potential of hzVSF in a series of pre-clinical tests including Hepatitis B & C virus and Influenza A virus in vitro and in vivo using several animal models. ImmuneMed did toxicological test for hzVSF and has planned to manufacture GMP drug product of hzVSF in Lonza. Now ImmuneMed expects to enter a phase 1 clinical trial in 2017 in South Korea. In addition, ImmuneMed has been developed the rapid diagnostic kits using lateral flow immunochromatographic assay for early detection of acute febrile illnesses. Now ImmuneMed are developing diagnostic kits including Dengue Haemorrhagic Fever, Typhoid Fever and etc. ImmuneMed has been holding ambitions which contribute to human health to be free from infectious diseases since it was founded in 2000.
NovaBiotics Ltd is a leading clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult to treat, medically unmet bacterial and fungal diseases. The Company’s advanced portfolio of antimicrobial therapeutic candidates targets large and important markets with significant unmet clinical needs, including Lynovex (in oral and inhaled form), an orphan drug candidate for cystic fibrosis (CF), Novexatin, a potential step change therapy for onychomycosis (being co-developed with and out-licensed to Taro Pharmaceuticals) and Novamycin, a novel antifungal peptide in development for the treatment of aspergillosis, candidiasis and cryptococcosis. Novexatin and Novamycin are among the first-in-class peptide anti-infectives which the company continues to derive from its proprietary antimicrobial peptide rational drug design platform. Lynovex and Nylexa have been developed as novel antimicrobial adjunct therapies from the company's more recently established aminothiol platform. NovaBiotics has a strong portfolio of granted and pending patents which are wholly owned by the Company. NovaBiotics was founded by our CEO, Dr. Deborah O’Neil in 2004 with the goal of fully developing and realizing the therapeutic and commercial potential of innate immune system effector based antibacterials and antifungals. NovaBiotics is a privately held company, based in Aberdeen, UK & Raleigh, NC, U.S.
Go to the profile of Serafim B. Tavares
Serafim B. Tavares

Independent Worker, Service Provider, [ (...) (e.g. Accountant / Auditor / Among others professional titles)], SBT, Serafim Bastos Tavares (SBT)

ProMIS Neurosciences, is a TSX listed Company (PMN.TO) headquartered in Toronto, Ontario, with offices in Cambridge MA at the Cambridge Innovation Center. The Company’s mission is to discover and develop precision medicine therapeutics for best in class treatment of neurodegenerative diseases, in particular Alzheimer’s disease (AD) and ALS. ProMIS Neurosciences’ proprietary target discovery engine is based on the use of two, complementary techniques. The Company applies its thermodynamic, computational discovery platforms—ProMIS™ & Collective Coordinates — to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, ProMIS is developing novel antibody therapeutics and specific companion diagnostics for AD and ALS. ProMIS has identified five target sites (epitopes) on toxic, misfolded strains of Amyloid beta, a root cause of AD, and created five antibodies specifically addressing these targets (without targeting amyloid beta monomer or plaque, known to be related to poor efficacy and side effects, respectively). ProMIS’ lead antibody product, PMN310, is in late preclinical development, with IND submission anticipated in late 2018. Large pharma companies have invested over $1BB in clinical trials targeting Amyloid beta over the last decade. Significant scientific conclusions can be drawn from results of these trials, indicating that best in class AD antibody therapy should target specifically the toxic, misfolded strains of Amyloid beta and not the other forms. ProMIS’ AD program is specifically designed and is on track to achieve this goal.
Nanowear is a wearable technology platform for medical diagnostics and chronic disease management based on the Company’s proprietary invention of textile-based nanosensors. Nanowear’s flagship product, SimpleSense, is the first-of-its-kind, non-invasive wearable garment for disease management of Congestive Heart Failure. SimpleSense uses these cloth-based, FDA-cleared (Class II) nanosensors to capture multi-channel ECG, Heart-rate variability, Respiratory Rate, Impedance Cardiography (stroke volume / cardiac output), thoracic impedance, actigraphy and cardio-phonography (S3 and S4 detection). Nanowear’s platform algorithmically scores the combination of these metrics for a unique, daily SimpleSense score alerting physicians and caretakers of advanced decompensating heart failure, reducing hospital admissions due to heart failure events. Nanowear’s proprietary sensor technology can also be licensed as a sensor consumable for already-built healthcare products in need of medical-grade sensor technology where exponentially higher signal-to-noise- ratios show capture is unaffected by body hair, moisture, sweat, and motion artifact is significantly reduced.
As the global leader in eye care, Alcon develops and manufactures innovative medicines and devices to serve the full life cycle of eye care needs. Alcon has recently has developed a platform for digitally assisted vitreoretinal surgery (DAVS) that provides a three-dimensional (3D) view of the back of the eye with excellent resolution, image depth of focus, clarity and color contrast.
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.
Go to the profile of Kathrin Szimak
Kathrin Szimak

Business Development Manager Out-Licensing, OncoQR

G-ray Switzerland SA is a development stage company, based in the State of Neuchâtel, Switzerland, with validated core competencies in monolithic CMOS integrated pixel array detector technology. Our mission is to deliver new solutions supporting the development of personal medicine through safer and better X-ray medical imaging. Our first product, the latenium™ detector, will deliver unprecedented price-performance ratio: we aim at establishing latenium™ as an industry-leading product together with established industry actors. The company addresses a large unmet need for low dose X-ray medical applications and brings deep expertise in the areas of: - compounds with ultra-high sensitivity - direct (covalent) bonding technology and the epitaxial growth of defect-free silicon-germanium absorber structures on silicon. We leverage the most recent technologies in material sciences, electronics and medical imaging to innovate and create long-term value for society and shareholders. We want to be a global healthcare technology provider and cultivate an open corporate culture with high ethical standards. We promote innovation, transparency, quality, collaboration, and performance in our interactions with suppliers, partners, the medical community and society. Finally, we also want our core technologies to bring benefits to the industrial sector, in particular in areas contributing to increased compliance and safety.
Novocure is an oncology company developing a profoundly different cancer treatment utilizing a proprietary therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Novocure’s commercialized product, Optune, is approved for the treatment of adult patients with glioblastoma. Novocure has ongoing or completed clinical trials investigating TTFields in brain metastases, non-small cell lung cancer, pancreatic cancer, ovarian cancer and mesothelioma.